The optimized formulation provides enhanced modulation of mitochondrial metabolism and fatty-acid oxidation. It also contributes to stronger regulation of inflammatory signaling pathways and improved mitochondrial adaptive responses.
ULTRA MOTS Pen is a mitochondrial peptide consisting of 16 amino acids encoded in the mtDNA's 12S rRNA and intended for precise subcutaneous administration via pre-mixed stabilized syringe-gun (usually totaling just 10 mg at a concentration of 5 mg/ml). This formulation utilizes patented PSM technology to ensure stable activity, where one click equals 0.05 mg (for example, 20 clicks equal 1 mg), simplifying dosing compared to traditional vials.
Main Benefits
The ULTRA MOTS peptide activates AMPK pathways, improving glucose uptake (via GLUT4), fatty acid oxidation, insulin sensitivity, and mitochondrial biogenesis for metabolic flexibility and stress resistance. It mimics exercise effects by enhancing endurance, fat utilization, and longevity signaling (such as PGC-1α, SIRT1). Studies show reduced obesity, improved glucose tolerance, and increased ATP production in models of metabolic stress.
Treatment Protocol
Use injection pen (abdomen, thigh); rotate injection sites. Standard protocols include:
Metabolic: 0.5–1 mg daily (10–20 clicks), 8–12 weeks, rest 4 weeks.
Endurance: 1 mg every two days (20 clicks), 8–12 weeks, rest 4 weeks.
Recovery: 5 mg daily (100 clicks), 8–12 weeks, rest 8 weeks.
Take in the morning or before training; store pen in refrigerator (1–7°C), stable up to 6–8 weeks after mixing. Cycle intake to avoid adaptation; monitor blood sugar/energy levels.
Combination with Other Peptides
ULTRA MOTS enhances synergy for amplified mitochondrial and metabolic effects:
NAD+/SS-31: Mitochondrial biogenesis, energy, antioxidant protection.
BPC-157: Tissue repair, resilience against stressors.
Epitalon: Telomere support, anti-aging action.
CJC-1295/Ipamorelin: Enhanced growth hormone secretion for fat reduction and body composition improvement (e.g., 1 mg MOTS-c plus each at 100 mcg).
Begin combination use with low dose (0.5 mg MOTS-c); experimental application only.
